Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Judith Gorelick

Neurological Surgery Shelton, CT Medical Doctor

NPI 1417962093 CMS profile 517662

330 Bridgeport Ave, Shelton, CT 06484

Open in the dashboard

General payments

$8,430

139 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Judith Gorelick of Shelton, CT is reported in the CMS Open Payments database as having received $8,430 across 139 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $608 12
2024 General $1,207 21
2023 General $1,464 39
2022 General $1,316 21
2021 General $99 4
2020 General $716 11
2019 General $3,020 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Judith Gorelick
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Judith Gorelick were reported at $608. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Judith Gorelick Neurological Surgery median Middle half National median
2019 $3,020 $582 $138–$3,006 $163
2020 $716 $294 $76–$2,174 $114
2021 $99 $387 $105–$2,432 $132
2022 $1,316 $542 $139–$2,989 $149
2023 $1,464 $534 $145–$2,697 $160
2024 $1,207 $574 $155–$3,046 $164
2025 $608 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $3,492 36 payments
  2. Globus Medical, Inc. $3,415 62 payments
  3. DePuy Synthes Sales Inc. $729 31 payments
  4. Orthofix Medical, Inc. $219 1 payment
  5. SI-BONE, Inc. $168 2 payments
  6. 4WEB, Inc. $150 1 payment
  7. Saluda Medical Americas, Inc. $149 1 payment
  8. Medical Device Business Services, Inc. $47 2 payments
  9. Sanara MedTech Inc. $24 1 payment
  10. Smith+Nephew, Inc. $24 1 payment
  11. Other $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $4,587 19 payments
  2. Food and Beverage $3,842 120 payments
Products named General payments · program years 2019–2025
  1. TRITANIUM $2,062 12 payments
  2. SERRATO $1,500 9 payments
  3. AERO $1,489 8 payments
  4. ExcelsiusGPS Robotic Navigation System Robotics $1,043 8 payments
  5. ES2 $944 5 payments
  6. Excelsius Robotics System $862 3 payments
  7. ExcelsiusGPS Robotic Navigation System Spine/Spine Surgery $607 6 payments
  8. XIA $599 5 payments
  9. OASYS $545 3 payments
  10. YUKON $545 3 payments
  11. Other $3,342 104 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

104

Median for Neurosurgery: 83

Drug cost

$816

Median for Neurosurgery: $872

Branded share of claims

0%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 49 $463
Methylprednisolone Generic 27 $238
Oxycodone Hcl Generic 14 $69
Prednisone Generic 14 $46

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 64 billing codes

Paid by Medicare

$101,300

Of which drugs: $253

Medicare patients

256

Average age 74

Services billed

1,040

150 women, 106 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 29%
Ischemic heart disease 29%
Depression 22%
Osteoporosis 20%
COPD 19%
Chronic kidney disease 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml A9579 Office 14 214 $253

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

139 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record